# US 2023/0390541 A1 · Dermal Patch for Transdermal Modulation of Ghrelin Pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390541 A1
- Document ID: US20230390541A1
- Status: Published application
- Kind: A1
- Application number: 18/235,940
- Filed: 2023-08-21
- Published: 2023-12-07
- Earliest claimed: 2019-07-26
- Assignees: Resarcion LLC
- Applicants: Resarcion, LLC
- Inventors: Edward A. Greenfield; Pedram HAMRAH; Reza MOLLAAGHABABA
- Web page: https://patentgrep.com/patent/US20230390541A1

## CPC

- A61M 37/0015: {by using microneedles}
- A61K 38/1729: {Cationic antimicrobial peptides, e.g. defensins}
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/0046: {Solid microneedles}
- A61M 2037/0061: {Methods for using microneedles}
- A61M 2210/04: Skin
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the innovation relate to a dermal patch, comprising a substrate; a set of projections coupled to the substrate and configured to be at least partially insertable into skin, at least a portion of each projection of the set of projections comprising a biodegradable material; and a ghrelin blocker material encapsulated in the plurality of projections. The set of projections are coupled to the substrate via an adhesive that is configured to be dissolved within the skin after the patch is applied to the skin for a predetermined time, thus resulting in separation of the set of projections from the substrate. Once embedded in the skin, the protrusions can degrade and release the anti-ghrelin antibody encapsulated therein. The released anti-ghrelin antibody can find its way into the subject's circulatory system.

## Claims

### Claim 1

A method of in-vivo modulation of ghrelin pathway in a subject, comprising:
applying a dermal patch including at least one of LEAP-2 peptide and a LEAP-2 peptide fragment to a subject's skin, wherein the dermal patch includes a plurality of projections configured to be insertable into the skin, at least a portion each of the projections including a biodegradable matrix material,
maintaining the patch on the skin for a sufficient time to allow the biodegradable material inserted into the skin to be at least partially dissolved so as to release the at least one of the LEAP-2 peptide and the LEAP-2 peptide fragment into the skin such that diffusion of the released at least one of the LEAP-2 peptide and the LEAP-2 peptide fragment into the subject's circulatory system results in modulation of the subject's appetite.

### Claim 2 (depends on 1)

The method of claim 1, wherein a concentration of said at least one of the LEAP-2 and the LEAP-2 fragment in said projections is in a range of about 0.1% to about 70% by weight.

### Claim 3 (depends on 1)

The method of claim 1, wherein a concentration of said at least one of the LEAP-2 and the LEAP-2 fragment in said projections is in a range of about 10% to about 60% by weight.

### Claim 4 (depends on 1)

The method of claim 1, wherein a concentration of said at least one of the LEAP-2 and the LEAP-2 fragment in said projections is in a range of about 20% to about 50% by weight.

### Claim 5 (depends on 1)

The method of claim 1, wherein a concentration of said at least one of the LEAP-2 and the LEAP-2 fragment in said projections is in a range of about 30% to about 40% by weight.

### Claim 6 (depends on 1)

The method of claim 1, wherein at least one of said projections comprises a channel in which the at least one of the LEAP-2 and the LEAP-2 fragment is disposed.

### Claim 7 (depends on 1)

The method of claim 1, wherein at least one of said projections comprises a plurality of polymeric particles encapsulating the at least one of the LEAP-2 and the LEAP-2 fragment.

### Claim 8 (depends on 7)

The method of claim 7, wherein the plurality of polymeric particles exhibit different sizes.

### Claim 9 (depends on 7)

The method of claim 7, wherein the plurality of particles are formed of different polymeric materials.

### Claim 10 (depends on 7)

The method of claim 7, wherein the plurality of particles exhibit different dissolution rates in the skin.

### Claim 11

A dermal patch, comprising:
a substrate;
a plurality of projections extending from the substrate and configured to be at least partially insertable into the skin,
at least one of LEAP-2 peptide and a LEAP-2 peptide fragment incorporated in said plurality of projections,
wherein said plurality of projections comprise a biocompatible material that is dissolved in the skin to allow release of said at least one of the LEAP-2 peptide and the LEAP-2 peptide fragment in the skin.

### Claim 12 (depends on 11)

The dermal patch of claim 11, wherein the plurality of projections comprises a plurality of micro-needles, at least some of the plurality of micro-needles are configured to be fully insertable into skin.

### Claim 13 (depends on 11)

The dermal patch of claim 11, wherein said biocompatible material comprises any of ultra-low viscosity carboxymethylcellulose (CMC), bovine serum albumin (BSV), and amylopectin.

### Claim 14 (depends on 11)

The dermal patch of claim 11, wherein at least one of said plurality of projections includes a channel in which the at least one of the LEAP-2 peptide and the LEAP-2 fragment is disposed.

### Claim 15 (depends on 11)

The dermal patch of claim 11, further comprising a plurality of polymeric particles in which the at least one of the LEAP-2 peptide and the LEAP-2 fragment is encapsulated.
